Comparison of Letermovir Versus High-Dose Valacyclovir for Cytomegalovirus Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation
Key Points
Letermovir shows improved efficacy in preventing cytomegalovirus infection post-transplantation.
In this study, lettermovir treatment reduced CMV reactivation rates by 30% compared to high-dose valacyclovir.
Analysis of allogeneic hematopoietic stem cell transplant patients indicates significant differences in medication outcomes.
Understanding these treatment differences highlights the need for tailored prophylactic strategies.
Like
Bookmark
Share
Like
Bookmark
Share
Comparison of Letermovir Versus High-Dose Valacyclovir for Cytomegalovirus Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation | Synapse